Survodutide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 15 registered trials.

Why this status

  1. 4 Oct 2023: Trial registered, NCT06066515
  2. 4 Oct 2023: Trial registered, NCT06066528
  3. 11 Oct 2023: Trial registered, NCT06077864
  4. 20 Nov 2023: Trial started, NCT06077864
  5. 25 Nov 2023: Trial started, NCT06066515
  6. 27 Nov 2023: Trial started, NCT06066528
  7. 19 Dec 2023: Trial registered, NCT06176365
  8. 16 Jan 2024: Trial started, NCT06176365
  9. 22 Jan 2024: Trial registered, NCT06214741
  10. 6 Feb 2024: Trial started, NCT06214741
  11. 13 Mar 2024: Trial registered, NCT06309992
  12. 2 Apr 2024: Trial started, NCT06309992

The trials

NCT03591718: A Study to Test Different Doses of BI 456906 in Patients With Obesity

State
Completed
Phase
Phase 1
People
131 taking part
Started
26 Jul 2018
Primary completion
20 Apr 2020
Arms
BI 456906
Results
None posted
Papers
doi:10.1111/dom.14948
  1. 19 Jul 2018: Trial registered
  2. 26 Jul 2018: Trial started
  3. 30 Apr 2020: Trial completed

NCT04667377: A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

State
Completed
Phase
Phase 2
People
387 taking part
Started
8 Mar 2021
Primary completion
15 Sep 2022
Arms
0.6 mg BI 456906, 2.4 mg BI456906, 3.6 mg BI 456906, 4.8 mg BI 456906
Results
Posted on the registry
Papers
doi:10.1016/s2213-8587(23)00356-x, doi:10.1111/dom.16167, doi:10.1111/dom.70861
  1. 14 Dec 2020: Trial registered
  2. 8 Mar 2021: Trial started
  3. 7 Oct 2022: Trial completed
  4. 2 Nov 2023: Trial results posted

NCT05296733: A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

State
Completed
Phase
Phase 1
People
82 taking part
Started
27 Apr 2022
Primary completion
29 Dec 2023
Arms
Part A: BI 456906: Cohort 1, Part A: BI 456906: Cohort 2, Part A: BI 456906: Cohort 3, Part A: BI 456906: Cohort 4, Part B: BI456906: Cohort 1, Part B: BI456906: Cohort 2, Part B: BI456906: Cohort 3
Results
None posted
Papers
doi:10.1016/j.jhep.2024.06.003
  1. 25 Mar 2022: Trial registered
  2. 27 Apr 2022: Trial started
  3. 29 Dec 2023: Trial completed

NCT06066515: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

State
Completed
Phase
Phase 3
People
726 taking part
Started
25 Nov 2023
Primary completion
2 Dec 2025
Arms
Survodutide 3.6 mg, Survodutide 6.0 mg
Results
None posted
Papers
doi:10.1056/nejmoa2600751, doi:10.1111/dom.70196
  1. 4 Oct 2023: Trial registered
  2. 25 Nov 2023: Trial started
  3. 20 Feb 2026: Trial completed

NCT06066528: A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

State
Completed
Phase
Phase 3
People
755 taking part
Started
27 Nov 2023
Primary completion
12 Dec 2025
Arms
Survodutide 3.6 mg, Survodutide 6.0 mg
Results
None posted
Papers
doi:10.1056/nejmoa2607219, doi:10.1111/dom.70263
  1. 4 Oct 2023: Trial registered
  2. 27 Nov 2023: Trial started
  3. 1 Apr 2026: Trial completed

NCT06077864: A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

State
Completed
Phase
Phase 3
People
5,530 taking part
Started
20 Nov 2023
Primary completion
1 Jun 2026
Arms
survodutide 3.6 mg, survodutide 6.0 mg
Results
None posted
Papers
doi:10.1016/j.jchf.2024.09.004, doi:10.1016/s0140-6736(26)02140-9
  1. 11 Oct 2023: Trial registered
  2. 20 Nov 2023: Trial started
  3. 30 Jun 2026: Trial completed

NCT06176365: A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease

State
Completed
Phase
Phase 3
People
274 taking part
Started
16 Jan 2024
Primary completion
3 Dec 2025
Arms
Survodutide - 3.6 mg, Survodutide - 6.0 mg
Results
None posted
Papers
doi:10.1111/dom.70862
  1. 19 Dec 2023: Trial registered
  2. 16 Jan 2024: Trial started
  3. 3 Dec 2025: Trial completed

NCT06214741: A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

State
Completed
Phase
Phase 3
People
307 taking part
Started
6 Feb 2024
Primary completion
29 Jul 2025
Arms
survodutide 3.6 mg, survodutide 4.8 mg
Results
None posted
Papers
doi:10.1007/s13300-026-01908-x
  1. 22 Jan 2024: Trial registered
  2. 6 Feb 2024: Trial started
  3. 28 Jan 2026: Trial completed

NCT06309992: A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

State
Completed
Phase
Phase 3
People
218 taking part
Started
2 Apr 2024
Primary completion
9 Oct 2025
Arms
Treatment arm
Results
None posted
Papers
doi:10.1111/apt.70020
  1. 13 Mar 2024: Trial registered
  2. 2 Apr 2024: Trial started
  3. 2 Dec 2025: Trial completed

NCT06492135: A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body

State
Completed
Phase
Phase 1
People
30 taking part
Started
12 Aug 2024
Primary completion
15 Apr 2025
Arms
Arm 1: Participants with a body mass index (BMI) ranging from ≥27.0 kg/m² to ≤40.0 kg/m², Arm 2: Participants with a body mass index (BMI) ranging from ≥24.0 kg/m² to <27.0 kg/m²
Results
None posted
  1. 9 Jul 2024: Trial registered
  2. 12 Aug 2024: Trial started
  3. 15 Apr 2025: Trial completed

NCT06745284: A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity

State
Under way
Phase
Phase 1
People
64 taking part
Started
26 Mar 2025
Primary completion
1 Nov 2026
Arms
Survodutide arm
Results
None posted
  1. 20 Dec 2024: Trial registered
  2. 26 Mar 2025: Trial started

NCT07413913: A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

State
Completed
Phase
Phase 1
People
56 taking part
Started
3 Mar 2026
Primary completion
28 May 2026
Arms
Survodutide formulation A then Survodutide formulation B2, Survodutide formulation B2 then Survodutide formulation A
Results
None posted
  1. 17 Feb 2026: Trial registered
  2. 3 Mar 2026: Trial started
  3. 11 Jun 2026: Trial completed

NCT07850050: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

State
Under way
Phase
Phase 3
People
600 planned
Started
25 Nov 2026
Primary completion
26 Jul 2028
Arms
Survodutide arm
Results
None posted
  1. 30 Sep 2026: Trial registered

NCT07850063: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease

State
Not started
Phase
Phase 3
People
600 planned
Started
25 Nov 2026
Primary completion
29 Apr 2029
Arms
Survodutide arm
Results
None posted
  1. 30 Sep 2026: Trial registered

NCT07855900: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

State
Under way
Phase
Phase 3
People
350 planned
Started
25 Nov 2026
Primary completion
6 Nov 2029
Arms
SWITCH cohort, INITIATION cohort
Results
None posted
  1. 2 Oct 2026: Trial registered

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as BI 456906, Survodutide formulation A, Survodutide formulation B2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.